Cited by 78Sexual Differentiation and DisordersAdrenal Hormones and DisordersMetabolism and Genetic Disorders

Profiles of 21-Carbon Steroids in 21-Hydroxylase Deficiency

Open access
Turcu, Adina F., Rege, Juilee, Chomic, Robert, Liu, Jiayan, Nishimoto, Hiromi K., Else, Tobias, Moraitis, Andreas G., Palapattu, Ganesh S. +2 more·2015·The Journal of Clinical Endocrinology & Metabolism

Abstract

Context: Marked elevations of 17-hydroxyprogesterone (17OHP) are characteristic of classic 21-hydroxylase deficiency (21OHD). Testing of 17OHP provides the basis for 21OHD diagnosis, although it suffers from several pitfalls. False-positive or false-negative results and poor discrimination of nonclassic 21OHD from carriers limit the utility of serum 17OHP and necessitate dynamic testing after cosyntropin stimulation when values are indeterminate. Objective: The objective was to provide a detailed characterization of 21-carbon (C21) steroids in classic 21OHD, which might identify other candidate steroids that could be employed for the diagnosis of 21OHD. Setting and Participants: Patients (11 women, 10 men) with classic 21OHD and 21 sex- and age-matched controls seen in a tertiary referral center were studied. Methods: C21 steroids in the peripheral sera from all subjects, as well as in media from cultured testicular adrenal rest tumor (TART) cells and normal adrenal (NA) cells, were analyzed using liquid chromatography/tandem mass spectrometry (10 steroids). Additionally, the dynamics of C21 steroid metabolism in TART and NA cells were assessed with radiotracer studies. Results: Five C21 steroids were significantly higher in 21OHD patients: 17OHP (67-fold; P < .01), 21-deoxycortisol (21dF; 35-fold; P < .01), 16α-hydroxyprogesterone (16OHP; 28-fold; P < .01), progesterone (2-fold; P < .01), and 11β-hydroxyprogesterone (11OHP; not detected in controls; P < .01). The same steroids were the highest in media from TART cells relative to the NA cells: 11OHP, 58- to 65-fold; 21dF, 30- to 41-fold; 17OHP, 9-fold; progesterone, 9- to 12-fold; and 16OHP, 7-fold. Conclusion: Measurement of 16OHP and 11OHP along with 17OHP and 21dF by liquid chromatography/tandem mass spectrometry might comprise a biomarker panel to accurately diagnose all forms of 21OHD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2015-1023

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The conventional steroid panel of patients with 21OHD has been expanded in recent years to include previously neglected androgens.

    “The conventional steroid panel of patients with 21OHD has been expanded in the recent years, to include previously neglected androgens (12–14).”

    From 24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency (2021) · cites this paper as [13]

    The Discussion (page unavailable) proposes expanding 21OHD testing beyond established biomarkers 17OHP and 21dF. But the proposed additions, 16OHP and 11OHP, are C21 steroids; this paper does not support the claim that the panel was expanded to include previously neglected androgens. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • A phase III trial including 122 patients with classic CAH revealed superior hormonal control during the early morning and early afternoon compared to patients receiving standard glucocorticoid therapy.

    “A phase III trial including 122 patients with classic CAH revealed superior hormonal control during the early morning and early afternoon compared to patients receiving standard glucocorticoid therapy (338,385).”

    From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [385]

    The Patient sera section describes a study of 21 adults with classic 21-hydroxylase deficiency and 21 matched controls, not a phase III treatment trial. Searches for the 122-patient trial, early-morning and early-afternoon hormonal control, and a comparison with standard glucocorticoid therapy found no passage reporting the claimed result. (LLM, conf=0.77)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

5 of the 52 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [1]1. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med. 2003;349:776 -788.

Cited by

Sorted by citations

Authors
Turcu, A. F., Rege, J., Chomic, R., Liu, J., Nishimoto, H. K., Else, T., Moraitis, A. G., Palapattu, G. S., Rainey, W. E., & Auchus, R. J.
Affiliations
  • Division of Metabolism, Endocrinology, and Diabetes (A.F.T., J.L., T.E., A.G.M., W.E.R., R.J.A.), Ann Arbor, Michigan 48109
  • University of Michigan (US)
  • Department of Urology (G.S.P.), Ann Arbor, Michigan 48109
Corresponding author
Auchus, Richard J.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2015-06-01
Volume
100
Issue
6
Pages
2283-2290
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2054459763
Cited by
77
References
52
Citations by year
2026: 2 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 4 · 2021: 10 · 2020: 7 · 2019: 11 · 2018: 3 · 2017: 13 · 2016: 6 · 2015: 4
FWCI
3.76
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Michigan (48109, DK089503)
  • National Institutes of Health (DK089503)
  • College of Pharmacy, University of Michigan
  • National Institute of General Medical Sciences (R01GM086596)
  • National Institute of Diabetes and Digestive and Kidney Diseases (U24DK097153, DK089503, F32DK103461, R01DK069950, P30DK089503)
  • Janssen Research and Development
  • Michigan Nutrition Obesity Research Center, Medical School, University of Michigan
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
21-hydroxylase deficiency, 17-hydroxyprogesterone, 21-deoxycortisol, 16α-hydroxyprogesterone, 11β-hydroxyprogesterone, steroid metabolism, cosyntropin stimulation
MeSH terms
Adrenal Hyperplasia, Congenital, Adrenal Rest Tumor, Adult, Cells, Cultured, Cortodoxone, Female, Humans, Hydroxyprogesterones, Male, Middle Aged, Progesterone, Testicular Neoplasms, Case-Control Studies, 17-alpha-Hydroxyprogesterone, Metabolome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review